Batu Biologics Recruits Dr. Vijay Mahant to SAB

Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm

Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board.

Read the full article at businesswire.com

Continue →
0

Batu Biologics selected to present at Cavendish Global Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.

Read the full article at businesswire.com

Continue →
0

Dr. Thomas Ichim joins as full-time CSO

Founder of Batu Biologics Expands Involvement as Chief Scientific Officer

Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.

Read the full article at businesswire.com

Continue →
0

Vice Chair of Immunology at TSRI joins SAB

Vice Chairman of Immunology at The Scripps Research Institute to Assist with ValloVax™ Clinical Development

Argyrios Theofilopoulos, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Completes Seed Round Financing

Batu Biologics Continues Fight in War Against Lung Cancer

Closure of $1 million seed round to support development of anti-angiogenic immune therapy, ValloVax™

Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.

Read the full article at businesswire.com

Continue →
0